MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s13054-026-06311-3

Медицинская библиотека · Critical care (London, England) · 2026

Evaluating plasma ferritin and suPAR as treatable traits for critically ill patients with COVID-19 treated with anakinra: an exploratory analysis of the immune modulation domain of the REMAP-CAP randomised clinical trial.

Boyle Andrew J, Ryan Elizabeth G, Berry Lindsay R, Berry Scott, Derde Lennie, Lawler Patrick R, Lorenzi Elizabeth, O'Kane Cecilia M, Shankar-Hari Manu, Veerdonk Frank van de, Gordon Anthony C, McAuley Daniel F, REMAP-CAP Immune Modulation Domain Investigators

СтатьяРандомизированное исследованиеПеревод в очереди

Аннотация

BACKGROUND

Identifying treatable traits in critically ill patients offers potential to enable a precision medicine approach to treatment. The aim of this exploratory analysis of the REMAP-CAP immune modulation domain was to evaluate whether plasma ferritin or soluble urokinase plasminogen activator receptor (suPAR) represent treatable traits for anakinra in critically ill patients with coronavirus disease (COVID-19).

METHODS

An exploratory analysis of patients randomised within the COVID-19 immune modulation domain of the REMAP-CAP trial was conducted. Adults within 24 h of receiving respiratory or cardiovascular organ support in an ICU with suspected or microbiologically confirmed COVID-19 were included. Plasma ferritin was measured at study sites, and plasma suPAR measured in stored plasma samples. The primary outcome was organ support-free days (OSFD) until day 21. Analyses were performed using a Bayesian cumulative logistic regression model, and results are presented as the posterior median odds ratio (OR), along with 95% credible intervals (CrI), for anakinra being superior to control.

RESULTS

In ferritin analyses, 1243 patients were included. Patients with increasing ferritin levels had numerically fewer OSFDs. The posterior probabilities of anakinra having benefit (OR > 1) were 64%, 71%, and 21% across increasing ferritin terciles, compared to 53% in analyses that did not adjust for ferritin levels. 145 patients were included in the suPAR analyses. Patients with high baseline plasma suPAR (≥ 6 ng/ml; n = 85) had numerically fewer OSFDs than patients with low plasma suPAR (-1.0 (-1.0, 9.0) vs. 13.0 (-1.0, 17.0)). The posterior probabilities of anakinra having benefit (OR > 1) were 94.8% (OR 2.28 [0.85-6.06]) in patients with low baseline suPAR, and 38.6% (OR 0.88 [0.39-2.00]) in patients with high baseline suPAR.

CONCLUSION

Plasma ferritin does not identify patients with COVID-19 who benefit from treatment with anakinra, whilst anakinra may be beneficial in patients with low, rather than high, baseline plasma suPAR. These hypothesis-generating findings contrast with the results of clinical trials in non-critically ill patients with COVID-19.

TRIAL REGISTRATION: NCT02735707. Date of trial registration: 06/04/2016.

Для цитирования: Boyle Andrew J, Ryan Elizabeth G, Berry Lindsay R, Berry Scott, Derde Lennie, Lawler Patrick R, Lorenzi Elizabeth, O'Kane Cecilia M, Shankar-Hari Manu, Veerdonk Frank van de, Gordon Anthony C, McAuley Daniel F, REMAP-CAP Immune Modulation Domain Investigators. Evaluating plasma ferritin and suPAR as treatable traits for critically ill patients with COVID-19 treated with anakinra: an exploratory analysis of the immune modulation domain of the REMAP-CAP randomised clinical trial.. Critical care (London, England). 2026. DOI: 10.1186/s13054-026-06311-3.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.